Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Herald of Medicine ; (12): 795-798, 2015.
Article in Chinese | WPRIM | ID: wpr-467799

ABSTRACT

Objective To prepare titanium dioxide (TiO2 ) nanoparticles with good near-infrared light and study the loading and release of doxorubicin. Methods The Sm doped TiO2 nanoparticles (Sm-TiO2 ) were synthesized using a modified solvothermal reaction and then observed with transmission electron microscope. The fluorescence spectrum, doxorubicin loading capacity and release profile were also determined. Results The obtained Sm-TiO2 nanoparticles with the length from 100-200 nm were fusiform and well dispersed. The emission wavelength was 640-670 nm. The drug loading capacity in water was 11. 5% . DOX in vitro was pH sensitive to release. Conclusion Sm-TiO2 nanoparticles have good near-infrared light, high drug loading capacity and controllable drug release are obtained and should be studied further more as a novel carrier.

2.
Chinese Journal of Primary Medicine and Pharmacy ; (12): 3725-3726, 2012.
Article in Chinese | WPRIM | ID: wpr-429952

ABSTRACT

Objective To observe the clinical efficacy of glutathione(GSH)to reduce hepatic involvement of statin therapy patients with hepatitis B markers positive.Methods 164 cases with hepatitis B markers positive were selected and divided into the treatment group(82 cases)and control group(82 cases).In a statin therapy with primary disease,at the same time,the control group using based protect liver therapy(both inosine,vitamin C),the treatment group using reduced glutathione intravenous drip(1.2g,one/d).After 12 weeks,the liver function was examined.Results Patients taking statins ALT,TB and DB levels obviously higher than before,had a statistically significant difference(t=2.66,1.98,2.13,P<0.05),the differences of observation index level in treatment group before and after treatment had no statistical difference(P>0.05),12 patients(14.6%)ALT level in treatment group were more than normal,0 case more than normal limit 3 times,control group respectively for 23 cases(28.1%),3 cases(3.7%),two groups had statistically significant difference(x2=4.672,5.304,all P<0.05).Conclusion GSH can obviously reduce hepatic involvement of statin therapy patients with hepatitis B markers positive.

SELECTION OF CITATIONS
SEARCH DETAIL